Iovance Biotherapeutics Inc.

06/13/2025 | Press release | Distributed by Public on 06/13/2025 15:15

Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 10, 2025, Jean-Marc Bellemin, the Chief Financial Officer and principal financial and accounting officer of Iovance Biotherapeutics, Inc. (the "Company"), provided the Company with written notice under his Executive Employment Agreement, dated November 23, 2020, that he would resign from the Company, effective July 10, 2025, to pursue other opportunities.

Iovance Biotherapeutics Inc. published this content on June 13, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 13, 2025 at 21:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io